A new device has just been cleared by the FDA and it’s drug free pain relief for dogs suffering from arthritis. Dr. Kathy Mitchener talks about a scientific breakthrough in pain management for dogs using an electromagnetic device.




New Website Offers FDA-Cleared Electrotherapy Devices for Pets and Horses


Montvale, NJ, August 26, 2009 — Ivivi Health Sciences today announced the official launch of a new division, Assisi Animal Health, and with it a new dedicated website, www.assisianimalhealth.com.  Assisi Animal Health has been created to meet the growing consumer demand seeking alternatives to pharmaceuticals to provide pain relief for dogs, cats and horses.  Assisi’s proprietary targeted pulsed electromagnetic field therapy technology (tPEMF™) is used for the treatment of pain and soft tissue injuries in pets and horses. “Many individuals seek non-pharmacological, non-invasive solutions for themselves,” says David Saloff, Executive Vice President and Co-Founder of Ivivi Health Sciences, makers of the devices. “Therefore, it’s completely understandable that they would seek similar alternatives for their pets and horses, many of whom are considered members of their family.”

The products are easy to use and cost-effective pain relief for dogs and other pets, and are supported by strong scientific and clinical work in humans and animals. In randomized controlled trials, Assisi’s targeted PEMF signals have produced significant improvements in tendon repair, wound healing and in pain and edema reduction.  Ivivi FDA-cleared PEMF devices provide a non-pharmacological, non-invasive, treatment for pain relief and soft tissue injuries, with no known adverse effects or side effects, for human use as well.

Products may be purchased online at the website, by phone or from select veterinarians, by licensed animal healthcare professionals or by consumers with a prescription. The website provides further information on the technology, as well as supporting research and clinical information.


About Assisi Animal Health


Assisi™ Animal Health is a division of Ivivi Health Sciences, Inc.  Assisi is focused on the delivery of non-invasive, non-pharmacological targeted pulsed electromagnetic field therapies for the small animal and equine markets. Assisi provides pain relief for dogs, cats, and horses.


About Ivivi Health Sciences, Inc.


Based in Montvale, NJ, Ivivi Health Sciences, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technologies, with a primary focus on treatment and resolution of inflammatory disorders and symptoms, including post-operative pain and swelling, osteoarthritis and vascular disorders.  Ivivi’s research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF™ technology.  tPEMF™ uses a pulsed magnetic field to deliver specific therapeutic electrical currents to inflamed tissues directly through dressings, casts, clothing, etc.  tPEMF™ is believed to modulate biochemical and physiological healing processes to help reduce related pain and associated symptoms.  The Company is currently engaged in ongoing research, supporting clinical adoption of its FDA-cleared technologies and seeking strategic marketing partners to develop sales and marketing efforts in specific medical markets.


Forward-Looking Statements


This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the trading of the Company’s securities on the OTC Bulletin Board or in the Pink Sheets. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company’s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company’s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company’s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company’s products and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s Form 10-KSB for the fiscal year ended March 31, 2008. The Company assumes no obligation to update the information contained in this press release.